Multivalent fibronectin based scaffold domain proteins
First Claim
Patent Images
1. A polypeptide comprising:
- (a) an N-terminal domain comprising a first fibronectin type III tenth domain (10Fn3), wherein the 10Fn3 domain (i) comprises a loop, AB;
a loop, BC;
a loop, CD;
a loop, DE;
a loop EF; and
a loop FG;
(ii) has at least one loop selected from loop BC, DE, and FG with an altered amino acid sequence relative to the sequence of the corresponding loop of the human 10Fn3 domain, (iii) comprises an amino acid sequence that is at least 60% identical to SEQ ID NO;
1, and (iv) binds to a first target molecule with a KD of less than 500 nM; and
(b) a C-terminal domain comprising a second fibronectin type Ill tenth domain (10Fn3), wherein the 10Fn3 domain (i) comprises a loop, AB;
a loop, BC;
a loop, CD;
a loop, DE;
a loop EF; and
a loop FG;
(ii) has at least one loop selected from loop BC, DE, and FG with an altered amino acid sequence relative to the sequence of the corresponding loop of the human 10Fn3 domain, (iii) comprises an amino acid sequence that is at least 60% identical to the amino acid sequence of SEQ ID NO;
1, and (iv) binds to a second target molecule with a KD of less than 500 nM;
wherein the polypeptide comprises the amino acid sequence of any one of SEQ ID NOs;
8-15, 29-31, and 63-64.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
68 Citations
20 Claims
-
1. A polypeptide comprising:
- (a) an N-terminal domain comprising a first fibronectin type III tenth domain (10Fn3), wherein the 10Fn3 domain (i) comprises a loop, AB;
a loop, BC;
a loop, CD;
a loop, DE;
a loop EF; and
a loop FG;
(ii) has at least one loop selected from loop BC, DE, and FG with an altered amino acid sequence relative to the sequence of the corresponding loop of the human 10Fn3 domain, (iii) comprises an amino acid sequence that is at least 60% identical to SEQ ID NO;
1, and (iv) binds to a first target molecule with a KD of less than 500 nM; and(b) a C-terminal domain comprising a second fibronectin type Ill tenth domain (10Fn3), wherein the 10Fn3 domain (i) comprises a loop, AB;
a loop, BC;
a loop, CD;
a loop, DE;
a loop EF; and
a loop FG;
(ii) has at least one loop selected from loop BC, DE, and FG with an altered amino acid sequence relative to the sequence of the corresponding loop of the human 10Fn3 domain, (iii) comprises an amino acid sequence that is at least 60% identical to the amino acid sequence of SEQ ID NO;
1, and (iv) binds to a second target molecule with a KD of less than 500 nM;
wherein the polypeptide comprises the amino acid sequence of any one of SEQ ID NOs;
8-15, 29-31, and 63-64. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
- (a) an N-terminal domain comprising a first fibronectin type III tenth domain (10Fn3), wherein the 10Fn3 domain (i) comprises a loop, AB;
-
15. A polypeptide comprising:
-
(a) an N-terminal domain comprising a first fibronectin type III tenth domain (10Fn3), wherein the 10Fn3 domain (i) comprises a loop, AB;
a loop, BC;
a loop, CD;
a loop, DE;
a loop EF; and
a loop FG;
(ii) has at least one loop selected from loop BC, DE, and FG with an altered amino acid sequence relative to the sequence of the corresponding loop of the human 10Fn3 domain, (iii) comprises an amino acid sequence that is at least 60% identical to SEQ ID NO;
1, and (iv) binds to a first target molecule with a KD of less than 500 nM;(b) a C-terminal domain comprising a second fibronectin type III tenth domain (10Fn3), wherein the 10Fn3 domain (i) comprises a loop, AB;
a loop, BC;
a loop, CD;
a loop, DE;
a loop EF; and
a loop FG;
(ii) has at least one loop selected from loop BC, DE, and FG with an altered amino acid sequence relative to the sequence of the corresponding loop of the human 10Fn3 domain, (iii) comprises an amino acid sequence that is at least 60% identical to the amino acid sequence of SEQ ID NO;
1, and (iv) binds to a second target molecule with a KD of less than 500 nM;
wherein the polypeptide comprises the amino acid sequence of any one of SEQ ID NOs;
65-70. - View Dependent Claims (16, 17, 18, 19, 20)
-
Specification